pharmaphorum1d
FDA says no to AZ's Fasenra for nasal polyp indication
AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...
National Institute for Health and Care Excellence17d
Awaiting development: Guidance and quality standards
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793] Technology appraisal guidance Baloxavir marboxil for treating influenza in babies under 1 year [TSID12141] Technology ...
National Institute for Health and Care Excellence17d
Awaiting development: Guidance and quality standards
Baloxavir marboxil for treating influenza in babies under 1 year [TSID12141] Technology appraisal guidance Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794] ...
pharmaphorum18d
Relief for AZ, Amgen as FDA okays severe asthma hope tezepelumab
They include Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's own IL-5 inhibitor Fasenra (benralizumab), which competes with GlaxoSmithKline's Nucala (mepolizumab) and Teva's ...